Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10452785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potential masking effects of salmeterol on airway inflammation in asthma.

  1998cited by this paper
• Effects of S-salbutamol on human isolated bronchus.

  1998cited by this paper
• Epidemiologic studies of beta agonists and asthma deaths.

  1998cited by this paper
• Asthma control during long term treatment with regular inhaled salbutamol and salmeterol

  1998cited by this paper
• Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.

  1998cited by this paper
• Case-control study of salmeterol and near-fatal attacks of asthma.

  1998cited by this paper
• A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.

  1997cited by this paper
• Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine.

  1997cited by this paper
• Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients.

  1997cited by this paper
• Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

  1997cited by this paper
• Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects.

  1997cited by this paper
• Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma.

  1997cited by this paper
• Differential responses of asthmatic airways to enantiomers of albuterol

  1996cited by this paper
• Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.

  1996cited by this paper
• An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.

  1996cited by this paper
• Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.

  1996cited by this paper
• Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol.

  1996cited by this paper
• Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.

  1996cited by this paper
• Effects of albuterol enantiomers on in vitro bronchial reactivity

  1996cited by this paper
• Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.

  1995cited by this paper
• Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.

  1995cited by this paper
• End of the New Zealand asthma mortality epidemic.

  1995cited by this paper
• Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol.

  1995cited by this paper
• Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.

  1995cited by this paper
• A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.

  1994cited by this paper
• Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics.

  1994cited by this paper
• Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma.

  1994cited by this paper
• Regular vs as-needed inhaled salbutamol in asthma control.

  1994cited by this paper
• Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge.

  1994cited by this paper
• The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

  1994cited by this paper
• Risks of salmeterol?

  1994cited by this paper
• Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol.

  1994cited by this paper
• Confounding by severity does not explain the association between fenoterol and asthma death

  1994cited by this paper
• Beta-agonist use and death from asthma.

  1994cited by this paper
• Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

  1994cited by this paper
• The effect of hypercapnia and hypoxemia on the cardiovascular responses to isoproterenol

  1994cited by this paper
• Asthma control during and after cessation of regular beta 2-agonist treatment.

  1993cited by this paper
• Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.

  1993cited by this paper
• High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol.

  1993cited by this paper
• Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.

  1993cited by this paper
• Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

  1993cited by this paper
• Use of near fatal asthma for investigating asthma deaths.

  1993cited by this paper
• Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.

  1993cited by this paper
• Regular inhaled salbutamol and airway responsiveness to allergen.

  1993cited by this paper
• The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies.

  1993cited by this paper
• Effect on airway responsiveness of six weeks treatment with salmeterol.

  1993cited by this paper
• Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?

  1993cited by this paper
• Cardiovascular effects of fenoterol under conditions of hypoxaemia.

  1992cited by this paper
• A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group.

  1992cited by this paper
• Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.

  1992cited by this paper
• The use of beta-agonists and the risk of death and near death from asthma.

  1992cited by this paper
• Fenoterol and death from asthma

  1992cited by this paper
• Beta-agonists and death from asthma.

  1992cited by this paper
• Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma.

  1992cited by this paper
• Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.

  1992cited by this paper
• Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management.

  1991cited by this paper
• Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

  1991cited by this paper
• Respiratory arrest in near-fatal asthma.

  1991cited by this paper
• Respiratory arrest in near-fatal asthma.

  1991cited by this paper
• Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow.

  1991cited by this paper
• Bronchial responsiveness during regular fenoterol therapy: four months prospective study.

  1991cited by this paper
• Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study.

  1991cited by this paper
• Asthma mortality and inhaled beta agonist therapy.

  1991cited by this paper
• The self-administration of inhaled beta agonist drugs during severe asthma.

  1990cited by this paper
• Regular inhaled beta-agonist treatment in bronchial asthma.

  1990cited by this paper
• Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.

  1990cited by this paper
• Salbutamol nebuliser and precipitation of critical cardiac ischaemia.

  1990cited by this paper
• Fenoterol and fatal asthma.

  1990cited by this paper
• Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

  1990cited by this paper
• Is current treatment increasing asthma mortality and morbidity?

  1989cited by this paper
• Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.

  1989cited by this paper
• Long-term effect of ipratropium bromide and fenoterol on the bronchial hyperresponsiveness to histamine in children with asthma.

  1989cited by this paper
• Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

  1989cited by this paper
• Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.

  1989cited by this paper
• The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness.

  1989cited by this paper
• Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans.

  1989cited by this paper
• Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

  1988cited by this paper
• Cardiac arrhythmias caused by nebulised beta-agonist therapy.

  1987cited by this paper
• Asthma mortality in New Zealand: a review with some policy implications.

  1987cited by this paper
• The pathogenesis and significance of bronchial hyper-responsiveness in airways disease.

  1987cited by this paper
• Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

  1987cited by this paper
• Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

  1985cited by this paper
• Effects of the beta2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium

  1985cited by this paper
• Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol.

  1984cited by this paper
• Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration.

  1982cited by this paper
• Mortality from asthma: a new epidemic in New Zealand

  1982cited by this paper
• Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma.

  1981cited by this paper
• Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine.

  1980cited by this paper
• Association between asthma mortality and isoproterenol aerosols: a review.

  1978cited by this paper
• Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.

  1977cited by this paper
• Sympathomimetic bronchodilator drugs.

  1976cited by this paper
• Intramyocardial diversion of coronary blood flow: effects of isoproterenol-induced subendocardial ischemia.

  1975cited by this paper
• FURTHER OBSERVATIONS ON THE CARDIOTOXICITY OF ISOPRENALINE DURING HYPOXIA

  1974cited by this paper
• Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations

  1974cited by this paper
• Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma.

  1972cited by this paper
• The cardio‐toxicity of isoprenaline during hypoxia

  1969cited by this paper
• Adverse effects of inhalation of excessive amounts of nebulized isoproterenol in status asthmaticus.

  1969cited by this paper
• Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols.

  1969cited by this paper
• Observations on recent increase in mortality from asthma.

  1968cited by this paper
• A clinical and experimental study of isuprel in spontaneous and induced asthma.

  1949cited by this paper

• Excessive Short-acting Beta-agonists Prescriptions in COPD Treated with Triple Inhaler Therapy: A Possible Marker of Frequent Exacerbations. A Retrospective Cohort Study

  2026cites this paper
• Biased Signaling and Its Role in the Genesis of Short- and Long-Acting β2‑Adrenoceptor Agonists

  2025cites this paper
• The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales

  2024cites this paper
• The airway smooth muscle and the pipe dream of better bronchodilators.

  2024cites this paper
• Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand

  2024cites this paper
• The Role of ICS-containing Rescue Therapy versus SABA Alone in Asthma Management Today.

  2024cites this paper
• High use of short-acting β2-agonists in COPD is associated with an increased risk of exacerbations and mortality

  2023cites this paper
• The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

  2023cites this paper
• Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.

  2023cites this paper
• THE ICS/FORMOTEROL RELIEVER THERAPY REGIMEN IN ASTHMA: A REVIEW.

  2023cites this paper
• Impact of R-Carvedilol on β2-Adrenergic Receptor-Mediated Spontaneous Calcium Release in Human Atrial Myocytes

  2022cites this paper
• Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis

  2022influential citation
• Position statement: asthma in Latin America. IS short-acting beta-2 agonist helping or compromising asthma management?

  2020cites this paper
• The odorant receptor OR2W3 on airway smooth muscle evokes bronchodilation via a cooperative chemosensory tradeoff between TMEM16A and CFTR

  2020cites this paper
• Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.

  2020cites this paper
• It is time to change the way we manage mild asthma: an update in GINA 2019

  2019cites this paper
• Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial.

  2019cites this paper
• Bitter Taste Receptors for Asthma Therapeutics

  2019cites this paper
• Antithetic regulation by b-adrenergic receptors of G q receptor signaling via phospholipase C underlies the airway b-agonist paradox

  2018cites this paper
• Overreliance link between asthmatic subjects and short-acting β2 agonists.

  2018cites this paper
• Taste and smell GPCRs in the lung: Evidence for a previously unrecognized widespread chemosensory system.

  2018cites this paper
• Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012).

  2017cites this paper
• Identification of patterns of factors preceding severe or life‐threatening asthma exacerbations in a nationwide study

  2017cites this paper
• Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma

  2017cites this paper
• Coupling of Airway Smooth Muscle Bitter Taste Receptors to Intracellular Signaling and Relaxation Is via G&agr;i1,2,3

  2017cites this paper
• A Novel in vivo System to Test Bronchodilators

  2017cites this paper
• University of Groningen Heterologous amplification of homologous beta-adrenoceptor desensitization in airway smooth muscle

  2017cites this paper
• Bronchodilator response following methacholine-induced bronchoconstriction predicts acute asthma exacerbations

  2016cites this paper
• Pleiotropic Effects of Bitter Taste Receptors on [Ca2+]i Mobilization, Hyperpolarization, and Relaxation of Human Airway Smooth Muscle Cells

  2015cites this paper
• Long-Acting Beta Agonists Enhance Allergic Airway Disease

  2015cites this paper
• The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis

  2015cites this paper
• Arrestin-dependent localization of phosphodiesterases.

  2014cites this paper
• Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma

  2014cites this paper
• Bitter taste receptor function in asthmatic and nonasthmatic human airway smooth muscle cells.

  2014cites this paper
• Reply: safety of short-acting β-agonists not a barrier to making asthma rescue and controller medications available over the counter.

  2014cites this paper
• Arrestins - Pharmacology and Therapeutic Potential

  2014cites this paper
• Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma.

  2014cites this paper
• Metrics of salbutamol use as predictors of future adverse outcomes in asthma

  2013cites this paper
• Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.

  2013cites this paper
• Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators

  2013cites this paper
• The role of Beta-arrestins in respiratory pathophysiology and tumorigenesis: going a step beyond the cell surface.

  2012cites this paper
• TAS2R activation promotes airway smooth muscle relaxation despite β(2)-adrenergic receptor tachyphylaxis.

  2012cites this paper
• Over-the-counter β2-agonist purchase versus script: a cross-sectional study.

  2012cites this paper
• Inhaled Budesonide/Formoterol Combination

  2012cites this paper
• Polycyclic aromatic hydrocarbons impair function of β2-adrenergic receptors in airway epithelial and smooth muscle cells.

  2011cites this paper
• Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma

  2011cites this paper
• Cardiovascular effects of chronic treatment with a β2-adrenoceptor agonist relieving neuropathic pain in mice.

  2011cites this paper
• Animal models of asthma: value, limitations and opportunities for alternative approaches.

  2011cites this paper
• Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma

  2010cites this paper
• Continúa descendiendo la mortalidad por asma en Uruguay. Período 1984-2008

  2010cites this paper
• An update on the safety of long-acting β-agonists in asthma patients using inhaled corticosteroids

  2010cites this paper
• Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.

  2010cites this paper
• Asthma Mortality and Long-Acting Beta2-Agonists in Five Major European Countries, 1994–2004

  2009cites this paper
• Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle.

  2009cites this paper
• Self-Management of Acute Asthma among Low-Income Urban Adults

  2009influential citation
• Therapeutic management of allergic diseases

  2009cites this paper
• The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

  2008cites this paper
• Three Generations of Ongoing Controversies Concerning the Use of Short Acting Beta-Agonist Therapy in Asthma: A Review

  2008cites this paper
• Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products.

  2008cites this paper
• Prolonged heterologous beta2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction.

  2008cites this paper
• Getting to the heart of asthma: can "beta blockers" be useful to treat asthma?

  2007cites this paper
• Heterogeneity of transcription factor expression and regulation in human airway epithelial and smooth muscle cells.

  2007cites this paper
• Bronchodilators, fatal asthma, rebound effect and similitude

  2007cites this paper
• Optimal Management of Asthma in Elderly Patients

  2007cites this paper
• Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.

  2007cites this paper
• Влияние симпатомиметиков на электрокардиографические показатели у больных бронхиальной астмой

  2007cites this paper
• Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.

  2007cites this paper
• β2-Agonists and bronchial hyperresponsiveness

  2006cites this paper
• Transcriptional response to persistent beta2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility.

  2006cites this paper
• Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle.

  2006cites this paper
• Heterologous amplification of homologous beta-adrenoceptor desensitization in airway smooth muscle

  2006cites this paper
• Relative myotoxic and haemodynamic effects of the β‐agonists fenoterol and clenbuterol measured in conscious unrestrained rats

  2006cites this paper
• The controversy over long-acting beta agonists: examining the evidence.

  2006cites this paper
• Treatment with (R)-albuterol has no advantage over racemic albuterol.

  2006cites this paper
• Heterologous amplification of homologous beta-adrenoceptor desensitization in airway smooth muscle

  2006cites this paper
• Heterologous amplification of homologous beta-adrenoceptor desensitization in airway smooth muscle

  2006cites this paper
• Haemodynamic responses to salbutamol and isometric exercise are altered in young adults with mild asthma

  2005cites this paper
• Asthma deaths and the athlete

  2005cites this paper
• Managing asthma in the real world

  2004cites this paper
• Traumatic deaths during U.S. Armed Forces basic training, 1977-2001.

  2004cites this paper
• Functional genomics of lung disease. Second annual Pittsburgh International Lung Conference, October 2003.

  2004cites this paper
• Review of proposed National Health Priority Area asthma indicators and data sources

  2004cites this paper
• The beta-agonist controversy revisited.

  2004cites this paper
• Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects

  2003cites this paper
• Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox

  2003cites this paper
• Managing Outpatient Asthma Exacerbations

  2003cites this paper
• Beta-2 mimetics and magnesium: true or false friends?

  2003cites this paper
• Inhalation therapy for bronchial asthma: strategies and targets

  2003cites this paper
• Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox.

  2003cites this paper
• Management of the Acute Exacerbation of Asthma

  2003cites this paper
• The effect of temperature on adrenergic receptors of alveolar type II cells of a heterothermic marsupial.

  2003cites this paper
• Managing outpatient asthma exacerbations

  2003cites this paper
• Beta-agonists.

  2002cites this paper
• Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.

  2002cites this paper
• Different action of IBMX, isoproterenol and rutin on orthovanadate-induced nitric oxide release in mouse macrophage cells.

  2002cites this paper
• Inhibition by fenoterol of human eosinophil functions including β2‐adrenoceptor‐independent actions

  2002cites this paper
• Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight.

  2002cites this paper
• The disease management approach to controlling asthma.

  2002cites this paper
• Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

  2002cites this paper
• Formoterol in clinical practice--safety issues.

  2001cites this paper